Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance

  1. Rebecca EK Mandt  Is a corresponding author
  2. Madeline R Luth
  3. Mark A Tye
  4. Ralph Mazitschek
  5. Sabine Ottilie
  6. Elizabeth A Winzeler
  7. Maria Jose Lafuente-Monasterio
  8. Francisco Javier Gamo
  9. Dyann F Wirth
  10. Amanda K Lukens  Is a corresponding author
  1. Harvard T H Chan School of Public Health, United States
  2. University of California, San Diego, United States
  3. Massachusetts General Hospital, United States
  4. GlaxoSmithKline, Spain
  5. Broad Institute, United States

Abstract

Drug resistance remains a major obstacle to malaria control and eradication efforts, necessitating the development of novel therapeutic strategies to treat this disease. Drug combinations based on collateral sensitivity, wherein resistance to one drug causes increased sensitivity to the partner drug, have been proposed as an evolutionary strategy to suppress the emergence of resistance in pathogen populations. In this study, we explore collateral sensitivity between compounds targeting the Plasmodium dihydroorotate dehydrogenase (DHODH). We profiled the cross-resistance and collateral sensitivity phenotypes of several DHODH mutant lines to a diverse panel of DHODH inhibitors. We focus on one compound, TCMDC-125334, which was active against all mutant lines tested, including the DHODH C276Y line, which arose in selections with the clinical candidate DSM265. In six selections with TCMDC-125334, the most common mechanism of resistance to this compound was copy number variation of the dhodh locus, although we did identify one mutation, DHODH I263S, which conferred resistance to TCMDC-125334 but not DSM265. We found that selection of the DHODH C276Y mutant with TCMDC-125334 yielded additional genetic changes in the dhodh locus. These double mutant parasites exhibited decreased sensitivity to TCMDC-125334 and were highly resistant to DSM265. Finally, we tested whether collateral sensitivity could be exploited to suppress the emergence of resistance in the context of combination treatment by exposing wildtype parasites to both DSM265 and TCMDC-125334 simultaneously. This selected for parasites with a DHODH V532A mutation which were cross-resistant to both compounds and were as fit as the wildtype parent in vitro. The emergence of these cross-resistant, evolutionarily fit parasites highlights the mutational flexibility of the DHODH enzyme.

Data availability

The raw whole-genome sequencing data generated in this study have been submitted to the NCBI Sequence Read Archive database (https://www.ncbi.nlm.nih.gov/sra/) under accession number PRJNA689594. Sanger sequencing of the PCR amplified dhodh locus have been submitted to GenBank (NCBI) under accession numbers MZ571149-MZ571158.

The following data sets were generated

Article and author information

Author details

  1. Rebecca EK Mandt

    Harvard T H Chan School of Public Health, Boston, United States
    For correspondence
    rebeccamandt@gmail.com
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7165-7876
  2. Madeline R Luth

    University of California, San Diego, San Diego, United States
    Competing interests
    No competing interests declared.
  3. Mark A Tye

    Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  4. Ralph Mazitschek

    Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  5. Sabine Ottilie

    University of California, San Diego, San Diego, United States
    Competing interests
    No competing interests declared.
  6. Elizabeth A Winzeler

    University of California, San Diego, San Diego, United States
    Competing interests
    Elizabeth A Winzeler, Sits on the advisory board of the Tres Cantos Open Lab Foundation.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4049-2113
  7. Maria Jose Lafuente-Monasterio

    GlaxoSmithKline, Tres Cantos, Spain
    Competing interests
    Maria Jose Lafuente-Monasterio, GlaxoSmithKline employee.
  8. Francisco Javier Gamo

    GlaxoSmithKline, Tres Cantos, Spain
    Competing interests
    Francisco Javier Gamo, GlaxoSmithKline employee.
  9. Dyann F Wirth

    Harvard T H Chan School of Public Health, Boston, United States
    Competing interests
    Dyann F Wirth, Sits on the advisory board of Medicines for Malaria Venture.
  10. Amanda K Lukens

    Broad Institute, Cambridge, United States
    For correspondence
    alukens@broadinstitute.org
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9560-7643

Funding

National Institutes of Health (R01 AI093716)

  • Rebecca EK Mandt
  • Dyann F Wirth
  • Amanda K Lukens

Bill and Melinda Gates Foundation (OPP1132451)

  • Rebecca EK Mandt
  • Maria Jose Lafuente-Monasterio
  • Francisco Javier Gamo
  • Dyann F Wirth
  • Amanda K Lukens

National Institutes of Health (T32 GM008666)

  • Madeline R Luth

ExxonMobil Foundation

  • Rebecca EK Mandt
  • Dyann F Wirth
  • Amanda K Lukens

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2023, Mandt et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 739
    views
  • 155
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rebecca EK Mandt
  2. Madeline R Luth
  3. Mark A Tye
  4. Ralph Mazitschek
  5. Sabine Ottilie
  6. Elizabeth A Winzeler
  7. Maria Jose Lafuente-Monasterio
  8. Francisco Javier Gamo
  9. Dyann F Wirth
  10. Amanda K Lukens
(2023)
Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance
eLife 12:e85023.
https://doi.org/10.7554/eLife.85023

Share this article

https://doi.org/10.7554/eLife.85023

Further reading

    1. Evolutionary Biology
    Julia D Sigwart, Yunlong Li ... Jin Sun
    Research Article

    A major question in animal evolution is how genotypic and phenotypic changes are related, and another is when and whether ancient gene order is conserved in living clades. Chitons, the molluscan class Polyplacophora, retain a body plan and general morphology apparently little changed since the Palaeozoic. We present a comparative analysis of five reference quality genomes, including four de novo assemblies, covering all major chiton clades, and an updated phylogeny for the phylum. We constructed 20 ancient molluscan linkage groups (MLGs) and show that these are relatively conserved in bivalve karyotypes, but in chitons they are subject to re-ordering, rearrangement, fusion, or partial duplication and vary even between congeneric species. The largest number of novel fusions is in the most plesiomorphic clade Lepidopleurida, and the chitonid Liolophura japonica has a partial genome duplication, extending the occurrence of large-scale gene duplication within Mollusca. The extreme and dynamic genome rearrangements in this class stands in contrast to most other animals, demonstrating that chitons have overcome evolutionary constraints acting on other animal groups. The apparently conservative phenome of chitons belies rapid and extensive changes in genome.

    1. Evolutionary Biology
    Mauna R Dasari, Kimberly E Roche ... Elizabeth A Archie
    Research Article

    Mammalian gut microbiomes are highly dynamic communities that shape and are shaped by host aging, including age-related changes to host immunity, metabolism, and behavior. As such, gut microbial composition may provide valuable information on host biological age. Here, we test this idea by creating a microbiome-based age predictor using 13,563 gut microbial profiles from 479 wild baboons collected over 14 years. The resulting ‘microbiome clock’ predicts host chronological age. Deviations from the clock’s predictions are linked to some demographic and socio-environmental factors that predict baboon health and survival: animals who appear old-for-age tend to be male, sampled in the dry season (for females), and have high social status (both sexes). However, an individual’s ‘microbiome age’ does not predict the attainment of developmental milestones or lifespan. Hence, in our host population, gut microbiome age largely reflects current, as opposed to past, social and environmental conditions, and does not predict the pace of host development or host mortality risk. We add to a growing understanding of how age is reflected in different host phenotypes and what forces modify biological age in primates.